

**Level 2, 66 Hunter Street  
Sydney NSW 2000**

**Tel: (61-2) 9300 3344**

**Fax: (61-2) 9221 6333**

**E-mail: [pnightingale@biotron.com.au](mailto:pnightingale@biotron.com.au)**

**Website: [www.biotron.com.au](http://www.biotron.com.au)**

23 October 2018

The Manager Companies  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

(4 pages by email)

Dear Madam

### **APPOINTMENT OF A DIRECTOR**

The Directors of Biotron Limited (the 'Company') are pleased to announce the appointment of Professor Stephen Locarnini as a Director of the Company.

Professor Locarnini, BSc(Hons), PhD, MBBS, FRC(Path), is currently a director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D. His current major research interests include viral hepatitis, hepatitis vaccines and antiviral chemotherapy with an emphasis on the basic virology of the various agents of hepatitis, the molecular pathogenesis of hepatitis, as well as prevention and public health control measures.

Curative treatments for hepatitis B infections with antiviral agents represent a major focus for Professor Locarnini who is also interested in intellectual property issues when applied to clinical and diagnostic virology. He is a named inventor on over 20 internationally granted patents.

He worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Virus Laboratory) from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL and subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998.


Professor Locarnini is the recipient of numerous awards including the European Association for the Study of Liver Disease (EASL) International Recognition Award and the Gastroenterological Society of Australia (GESA) Distinguished Research Prize. He is author of 289 peer-reviewed articles, 24 invited editorials and 100 book chapters and reviews and every year delivers numerous invited, plenary, and named lectures at major international meetings and conferences.

Professor Locarnini currently has an academic appointment at the University of Melbourne.

He is a member of the Scientific Advisory Board of a number of emerging as well as established pharmaceutical and biotechnology companies. In 2017, he co-founded the biotech start-up company CLEAR-B with the Morningside-Newton Investment group in Boston, USA focusing on curative strategies for chronic hepatitis B. He is also the Hepatitis Virus Editor for Antiviral Therapy.

In accordance with Listing Rule 3.19A, I attach Appendix 3X, an Initial Director's Interest Notice for Stephen Locarnini.

Yours faithfully

A handwritten signature in black ink, appearing to read 'PJN', with a stylized flourish at the end.

Peter J. Nightingale  
Company Secretary

pjn9637

# Appendix 3X

## Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

|                       |                           |
|-----------------------|---------------------------|
| <b>Name of entity</b> | <b>BIOTRON LIMITED</b>    |
|                       | <b>ABN 60 086 399 144</b> |

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                           |
|----------------------------|---------------------------|
| <b>Name of Director</b>    | Stephen Alister LOCARNINI |
| <b>Date of appointment</b> | 23 October 2018           |

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |
|---|
| <b>Number &amp; class of securities</b> |
| Nil                                     |

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

|  |   |
|--|---|
| <b>Name of holder &amp; nature of interest</b><br>Note: Provide details of the circumstances giving rise to the relevant interest. | <b>Number &amp; class of Securities</b> |
| Nil  | Nil                                     |

+ See chapter 19 for defined terms.

### Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | Nil |
| <b>Nature of interest</b>  | N/A |
| <b>Name of registered holder<br/>(if issued securities)</b>      | N/A |
| <b>No. and class of securities to<br/>which interest relates</b> | N/A |

---

+ See chapter 19 for defined terms.